Shares of Jazz Pharmaceuticals PLC slid Wednesday morning, a day after the Irish drugmaker said in a regulatory filing that the Food and Drug Administration could approve a competitor's generic version of its top-seller, narcolepsy treatment Xyrem.Well, I guess that explains those outrageous price hikes. They know this is coming. They're going to squeeze as much money out of you as they can while they still can.
The Dublin-based company said in a quarterly report filed with the Securities and Exchange Commission that U.S. regulators could approve a generic version made by Roxane Laboratories Inc. Jazz filed a lawsuit in late 2010 against Roxane over that company's application for approval of the generic.
Xyrem sales jumped 60 percent in the first quarter to $117.5 million, which helped Jazz report better-than-expected results for the quarter.
Look at that. 117 million dollars. In one quarter.
No wonder they spent that much on a similar drug to try to prevent this from happening.
Gosh that would buy a lot of gluten-free food...
